Canadian Adaltis Aquires Diagnostics Distributor in China
Mr. Pierre Larochelle, President and Chief Executive Officer of Adaltis Inc. said "This transaction is an important step towards our objective of building a strong commercial presence in China and South-East Asia. We are very pleased to have completed this transaction with CITIC Pacific, our partner with whom we have established a joint venture for the manufacturing of our in-vitro diagnostic products."
"Adaltis is proceeding efficiently with its plan to grow in key emerging Asian markets. With the acquisition of DCH Healthcare Products, we will now have our most significant global sales force on the ground in China and Hong Kong, selling Adaltis products. Through our sales force in China and Hong Kong, we will be able to accelerate further in China the commercial launch of our new diagnostic system, Eclectica, as well as to enhance further the value of our important infectious disease product platform" said Mr. Larochelle.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.